earnings
confidence high
sentiment positive
materiality 0.80
QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY
QuidelOrtho Corp
2025-Q3 EPS reported
-$14.79
revenue$2,006,600,000
- Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
- Adjusted EBITDA margin improved 180 bps to 25%; full-year guidance maintained at 22%.
- Labs +4%, IH +5%, Triage +7% (constant currency); non-respiratory up 6% CC.
- Respiratory revenue $112M (-32% YoY); COVID sales down 63%.
- Pending LEX Diagnostics acquisition on track; VITROS High Sensitivity Troponin cleared in U.S.